IMV (NYSE:IMV) Receives “Buy” Rating from Echelon Wealth Partners

IMV (NYSE:IMV)‘s stock had its “buy” rating reissued by equities researchers at Echelon Wealth Partners in a note issued to investors on Tuesday, AnalystRatings.com reports. They currently have a $12.25 price target on the stock. Echelon Wealth Partners’ price objective indicates a potential upside of 372.97% from the stock’s previous close.

IMV has been the subject of a number of other research reports. Zacks Investment Research downgraded shares of IMV from a “buy” rating to a “hold” rating in a research report on Saturday, October 26th. Raymond James set a $10.00 price target on shares of IMV and gave the stock an “outperform” rating in a research report on Thursday, November 7th. HC Wainwright reissued a “buy” rating and set a $11.50 price target on shares of IMV in a research report on Monday. Finally, Wells Fargo & Co started coverage on shares of IMV in a research report on Monday, October 28th. They set a “market perform” rating for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. IMV has a consensus rating of “Buy” and a consensus target price of $9.60.

Shares of IMV traded up $0.04 during mid-day trading on Tuesday, reaching $2.59. 2,232 shares of the stock traded hands, compared to its average volume of 19,894. The stock has a fifty day simple moving average of $2.71 and a 200 day simple moving average of $3.14. IMV has a 12-month low of $2.25 and a 12-month high of $7.07.

IMV (NYSE:IMV) last posted its quarterly earnings data on Friday, November 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.03). The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.05 million.

Hedge funds have recently added to or reduced their stakes in the company. Bank of Montreal Can boosted its holdings in IMV by 17.5% in the second quarter. Bank of Montreal Can now owns 88,889 shares of the company’s stock worth $260,000 after purchasing an additional 13,228 shares during the period. Hartford Financial Management Inc. boosted its holdings in IMV by 9.6% in the third quarter. Hartford Financial Management Inc. now owns 38,098 shares of the company’s stock worth $94,000 after purchasing an additional 3,348 shares during the period. Royal Bank of Canada boosted its holdings in IMV by 3.6% in the second quarter. Royal Bank of Canada now owns 98,676 shares of the company’s stock worth $288,000 after purchasing an additional 3,453 shares during the period. Citadel Advisors LLC acquired a new position in IMV in the second quarter worth $37,000. Finally, Morgan Stanley boosted its holdings in IMV by 260.5% in the second quarter. Morgan Stanley now owns 90,368 shares of the company’s stock worth $264,000 after purchasing an additional 65,300 shares during the period.

IMV Company Profile

IMV, Inc is a clinical-stage biopharmaceutical company, which engages in the development of cancer immunotherapies and infectious disease vaccines. The firm’s patented platform, DepoVax, provides controlled and prolonged exposure of antigens and adjuvant to the immune system. The company was founded by Warwick Kimmins and Brian Lowe on March 28, 2000 and is headquartered in Halifax, Canada.

See Also: What is a balanced fund?

Analyst Recommendations for IMV (NYSE:IMV)

Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.